Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RXRX

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

Biotechs on the Brink: 2 Stocks With Huge Potential

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

1 AI Biotech Stock That Just Scored a Major Milestone

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

inkl

Read news from The Economist, FT, and more,
with one subscription

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

Recursion Catapults 78% On Nvidia Investment For AI In Drug Development

Recursion Catapults 78% On Nvidia Investment For AI In Drug Development

Recursion snagged a $50 million investment from Nvidia on Wednesday to work on drug development using AI, and RXRX stock nearly doubled.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intuitive Surgical

Recursion Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

276,909 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play